Eatontown, NJ, October, 31 2014. Avet Pharmaceuticals Inc. (“Avet”) announced the immediate availability of sterile Rifampin for injection, USP, containing 600mg/vial. This launch adds to Avet’s growing portfolio of generic injectable products. Rifampin is the AP rated generic equivalent to the antibiotic drug Rifadin® IV*. It is indicated for the treatment of all forms of tuberculosis. According to IMS data for the twelve-months ended August 2014, the U.S. market for Rifampin for injection is approximately $36.2 million.